Testing effectiveness (Phase 2)Ended earlyNCT01625741
What this trial is testing
Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy
Who this might be right for
Chronic Lymphocytic Leukemia
Cliniques universitaires Saint-Luc- Université Catholique de Louvain 6